A good obesity evaluation asks four questions, not one: what's driving the weight, what it's doing to metabolic and liver health, what a meaningful goal would be (rarely just the scale), and what — if anything — to treat. These cases work through that reasoning. They're teaching examples, not prescriptions, and not a substitute for a clinician.
Teaching tool. De-identified, composite, educational cases — not real patients and not practice data. Every case is illustrative; management is individualized with a clinician.
How to read these cases
Each case follows the same five-part structure the W8Experts method uses in clinic:
- What's happening — the clinical picture.
- What should be evaluated — the workup that actually changes decisions.
- Treatment options — what's on the table, evidence-graded.
- Trade-offs — the honest cost/benefit of each path.
- What would change management — the findings that would move the plan.
These are composite, de-identified teaching cases, not real individuals. Numbers used for illustration are labelled as examples. Nothing here is individualized medical advice. The recurring lesson is the site's spine: don't treat the scale — treat the person.
Case 1 · 45-year-old man, BMI 34, prediabetes
What's happening. A 45-year-old man with a BMI of 34 (class I obesity) and an A1c in the prediabetes range. Weight has crept up over 15 years; he has a family history of type 2 diabetes. He feels well and has no symptoms — which is exactly why this is a decision point, not a crisis.
What should be evaluated. Weight and medication history, sleep (screen for obstructive sleep apnea), diet and activity pattern, and eating behaviour. Labs: A1c and fasting glucose to confirm prediabetes, lipid panel, blood pressure, and — because central adiposity plus dysglycaemia is the classic MASLD setup — a FIB-4 and consideration of liver imaging even if enzymes are normal. Waist circumference and, ideally, body composition.
Treatment options. - Intensive lifestyle change — structured nutrition plus resistance and aerobic activity. In prediabetes, sustained ~5–7% weight loss substantially reduces progression to diabetes (Grade A 🟢, classic diabetes-prevention data). → Nutrition, Exercise & Muscle - Metformin — modest weight and glycaemic effect; often considered in prediabetes with additional risk factors (Grade A 🟢 for diabetes prevention). - GLP-1 / incretin therapy — effective for both weight and glycaemia, but the decision turns on the whole picture, not the BMI alone. → Should I take a GLP-1?
Trade-offs. Lifestyle change is the foundation and carries broad benefit, but durable adherence is hard and prediabetes often progresses anyway. Metformin is cheap and safe but modest. Starting an incretin now is more effective for weight and glucose, but means committing to a long-term, ongoing therapy and its costs and side effects for someone who currently feels well.
What would change management. Progression to diabetes-range A1c, a rising FIB-4 or elastography showing fibrosis, discovery of significant sleep apnea, or failure of a genuine lifestyle trial would all strengthen the case for pharmacotherapy. Confirmed advanced fibrosis or established diabetes reframes the goal from "prevent" to "treat and protect organs."
Questions patients ask.
My blood sugar is only "pre" — can I just wait and watch?
Watching is reasonable only if it's active: a real lifestyle trial with periodic A1c and a fibrosis-risk check. Prediabetes often progresses, so "waiting" without a plan tends to become "diagnosing diabetes later." Grade A 🟢Do I need a GLP-1 at BMI 34?
Not automatically. It's an option, not an obligation — the decision depends on your glucose trajectory, liver and CV risk, sleep, and how a lifestyle trial goes. See the GLP-1 decision tool. Grade B 🟡Case 2 · 52-year-old woman, menopause, BMI 31
What's happening. A 52-year-old woman, recently postmenopausal, BMI 31, with new central weight gain and a shift toward abdominal fat despite little change in her diet. She's frustrated that "nothing works like it used to."
What should be evaluated. Menopausal status and symptoms, weight-history timeline against the menopause transition, sleep, mood, and activity. Labs: A1c, lipids, thyroid (to exclude a contributing thyroid disorder, not to over-attribute), and a FIB-4 given rising cardiometabolic risk after menopause. Waist circumference and body composition — muscle preservation matters here.
Treatment options. - Lifestyle with a resistance-training emphasis — protects muscle and bone during a period of accelerated loss of both. → Exercise & Muscle - Menopause hormone therapy (MHT) — treats menopausal symptoms and modestly affects fat distribution, but is not a weight-loss drug; framed for its own indications. → Menopause & Weight · deeper detail at MenoExperts - GLP-1 / incretin therapy — effective for weight in this group; decision individualized. → Semaglutide, Tirzepatide
Trade-offs. MHT can help symptoms and quality of life but should not be sold as a weight solution. Incretins work but commit to long-term therapy and its costs. The menopause transition raises visceral fat and CV risk, so the goal is metabolic protection and function, not just the scale number.
What would change management. New diabetes or dyslipidaemia, a rising FIB-4, disabling menopausal symptoms (shifts MHT calculus), or significant muscle/bone loss on assessment would all reshape priorities.
Questions patients ask.
Did menopause cause my weight gain?
Menopause shifts fat toward the abdomen and accelerates muscle and bone loss, and midlife brings other changes too. It contributes, but it rarely explains everything — which is why the plan targets muscle, metabolism and CV risk, not just weight. Grade B 🟡 → Menopause & WeightWill hormone therapy make me lose weight?
No — MHT is for menopausal symptoms and has only modest effects on fat distribution. It's a reasonable therapy on its own merits, not a weight-loss drug. Grade B 🟡Case 3 · 38-year-old woman with PCOS
What's happening. A 38-year-old woman with polycystic ovary syndrome — irregular cycles, signs of hyperandrogenism, insulin resistance — and difficulty losing weight. She may also be trying to conceive, which changes the medication calculus.
What should be evaluated. Confirm the PCOS picture, screen for insulin resistance and dysglycaemia (A1c, fasting glucose), lipids, blood pressure, and FIB-4 (PCOS carries excess MASLD risk). Above all, pregnancy intent and timing, because GLP-1s are avoided in pregnancy and around conception.
Treatment options. - Lifestyle + resistance training — even modest weight loss can improve ovulation, cycles and insulin sensitivity (Grade A 🟢). → PCOS & Weight - Metformin — improves insulin resistance; sometimes used for cycle regularity (Grade B 🟡). - GLP-1 / incretin therapy — effective for the weight and metabolic component (Grade B 🟡 for PCOS specifically), but avoided if pregnancy is planned or possible — stop well before conception. → Should I take a GLP-1? - Fertility-directed care where conception is the goal.
Trade-offs. Weight loss helps PCOS across the board, but the most effective pharmacotherapy (incretins) collides directly with pregnancy plans. Sequencing matters: for someone conceiving soon, the plan looks very different than for someone deferring pregnancy for years.
What would change management. Pregnancy intent is the deciding variable — it can take GLP-1s off the table entirely. New diabetes, a rising FIB-4, or the tirzepatide oral-contraceptive interaction (backup contraception needed at start/dose increase) also change the plan.
Questions patients ask.
Can I take a GLP-1 for PCOS if I want to get pregnant?
Not while trying to conceive. GLP-1s are avoided in pregnancy and should be stopped well before — for some agents about two months ahead given the long half-life. If pregnancy is the near-term goal, the plan focuses elsewhere. Grade A 🟢Will losing weight fix my PCOS?
It often improves cycles, ovulation and insulin resistance, sometimes substantially — but PCOS is managed, not "fixed," and results vary. Grade A 🟢 → PCOS & WeightCase 4 · 60-year-old man, obesity + low testosterone + sleep apnea
What's happening. A 60-year-old man, BMI 36, with fatigue, low libido, a low measured testosterone, and loud snoring with witnessed apneas. This is a classic interlocking cluster: obesity lowers testosterone and drives sleep apnea, and each worsens the others.
What should be evaluated. Confirm sleep apnea with testing (this is often the highest-yield finding). Repeat morning testosterone with appropriate context before labelling hypogonadism, plus the metabolic workup (A1c, lipids, FIB-4). Assess CV risk. → Men's Health & Obesity
Treatment options. - Treat the sleep apnea (e.g., CPAP) — improves symptoms and CV risk independent of weight (Grade A 🟢). - Weight loss — often raises testosterone and reduces apnea severity, addressing the root of the cluster. Tirzepatide is FDA-approved for moderate-to-severe OSA in adults with obesity (SURMOUNT-OSA) — a single therapy targeting two problems (Grade A 🟢). → Tirzepatide - Testosterone therapy — a hormone question best evaluated in its own right; obesity-related low testosterone frequently improves with weight loss, so weight loss is often addressed first. (Men's-hormone detail is covered in depth by TestoExperts — forthcoming; until it launches, this routes to the practice men's-health page.)
Trade-offs. Reflexively prescribing testosterone without addressing weight and sleep can miss the reversible driver and carries its own considerations (fertility, haematocrit, CV debate). Weight loss addresses the cause but is slower. CPAP works but requires adherence.
What would change management. Persistently low testosterone after meaningful weight loss (points toward primary hypogonadism), severe OSA, established CV disease, or fertility goals would each reshape the plan.
Questions patients ask.
Should I start testosterone, or lose weight first?
Obesity and sleep apnea both suppress testosterone, and it often rises with weight loss and treated apnea — so addressing those first is common. Testosterone therapy is a separate decision with its own trade-offs. Grade B 🟡 → deeper men's-hormone detail at TestoExperts (forthcoming).Can a weight-loss drug treat my sleep apnea?
Tirzepatide is FDA-approved for moderate-to-severe OSA in adults with obesity, reducing apnea severity via weight loss. It doesn't replace CPAP for everyone, but it can treat two problems at once. Grade A 🟢 → TirzepatideCase 5 · 35-year-old woman, obesity + binge-eating disorder
What's happening. A 35-year-old woman with class II obesity and recurrent binge-eating episodes with loss of control and distress. The eating behaviour is central — treating the weight without treating the disorder tends to fail and can cause harm.
What should be evaluated. A proper eating-behaviour and mental-health assessment (screen for binge-eating disorder, depression, anxiety, history of restriction/purging), plus the standard metabolic workup. Understand the relationship with food, dieting history, and any prior harm from restrictive approaches.
Treatment options. - Structured psychological therapy — CBT for binge-eating disorder is first-line and effective (Grade A 🟢). → Mental Health & Obesity - Pharmacotherapy for BED — certain agents have evidence for reducing binge frequency; choice is individualized. - GLP-1 therapy — reduces appetite and "food noise" and can help weight, but is not a treatment for the eating disorder itself and should not replace psychological care; started thoughtfully and with monitoring (Grade B 🟡).
Trade-offs. Aggressive dietary restriction can worsen binge-eating and is potentially harmful. Medications may reduce weight without addressing the disorder driving it. The order of operations matters — behavioural stability often comes first, or in parallel.
What would change management. Active purging, severe depression or suicidality, or an unstable eating disorder would prioritise mental-health treatment and make weight-focused pharmacotherapy secondary until stabilised.
Questions patients ask.
Will a GLP-1 cure my binge eating?
No. GLP-1s can reduce appetite and food preoccupation and may help some people, but binge-eating disorder is treated with structured psychological therapy (and sometimes specific medications). Medication isn't a substitute for that care. Grade B 🟡 → Mental Health & ObesityIs dieting harder to do safely with an eating disorder?
Yes — restrictive dieting can worsen binge-eating and cause harm, which is why the eating disorder is addressed first or alongside any weight plan, not ignored. Grade A 🟢Case 6 · 70-year-old man, obesity + sarcopenia
What's happening. A 70-year-old man with obesity and low muscle mass and strength — sarcopenic obesity. He's had some unintentional decline in function and grip strength. Here, losing weight the wrong way could make him weaker, not healthier.
What should be evaluated. Function and strength (gait speed, grip, chair-stand), body composition rather than BMI alone, nutrition (especially protein intake), falls risk, and the metabolic and liver picture. Distinguish lean mass / skeletal muscle / strength / function — they are not the same thing.
Treatment options. - Resistance training + adequate protein — the cornerstone; protects and can build muscle while reducing fat (Grade A 🟢). → Exercise & Muscle - Cautious, muscle-aware weight loss — any pharmacotherapy is paired with resistance training and protein to limit lean-mass loss; the goal is fat loss with function preserved. → GLP-1 & Muscle Loss - Function-first goals — mobility, independence and strength outrank a target weight.
Trade-offs. Rapid or unsupported weight loss in an older adult risks accelerating muscle and bone loss and worsening frailty. But leaving obesity untreated has its own costs (mobility, metabolic, liver). The balance favours slower, resistance-supported loss with function as the endpoint.
What would change management. Falls, fractures, rapid functional decline, or evidence of significant lean-mass loss would shift the emphasis toward strength and nutrition and away from aggressive weight reduction.
Questions patients ask.
Isn't losing weight always good at my age?
Not if it costs you muscle and function. In older adults the aim is fat loss with strength preserved — that means resistance training and enough protein, and slower, monitored loss rather than rapid drops. Grade A 🟢 → Exercise & MuscleDo weight-loss drugs cause muscle loss?
Some lean mass is lost with any substantial weight loss, including with GLP-1s — but "lean mass" on a scan isn't the same as strength, and resistance training plus protein protect muscle and function. Grade B 🟡 → GLP-1 & Muscle LossCase 7 · Obesity but normal metabolic labs ("metabolically healthy?")
What's happening. A person with obesity (say BMI 33) whose A1c, lipids, blood pressure and liver enzymes are all normal — sometimes labelled "metabolically healthy obesity." The question: does this need treatment at all?
What should be evaluated. Confirm the metabolic picture is genuinely normal (including a FIB-4, since normal enzymes don't exclude liver disease), waist/body composition, sleep, joints/mobility, and family history. And assess the trajectory — "metabolically healthy" is often a stage, not a stable state.
Treatment options. - Lifestyle foundation + monitoring — reasonable for a genuinely low-risk person; track metabolic markers over time (Grade B 🟡). - Shared-decision pharmacotherapy — considered if risk factors emerge, function is affected, or the person prioritises it; not mandatory purely on BMI.
Trade-offs. Over-treating a low-risk person exposes them to cost and side effects for uncertain benefit. Under-monitoring risks missing conversion to metabolically unhealthy obesity, which is common over time. The honest answer is "watch actively, treat if the picture changes."
What would change management. New dysglycaemia, dyslipidaemia, hypertension, a rising FIB-4 or discovered fibrosis, sleep apnea, or joint/mobility problems would move this from "monitor" to "treat." → Can you be obese and healthy?
Questions patients ask.
If all my labs are normal, am I healthy?
Possibly — but "metabolically healthy obesity" is often a phase that converts over time, and normal enzymes don't rule out liver disease. Active monitoring (including a FIB-4) is wiser than assuming it's permanent. Grade B 🟡 → Normal enzymesDo I have to treat obesity if I feel fine?
Not automatically. With genuinely low risk, a lifestyle foundation plus monitoring is defensible. Treatment becomes more compelling if risk factors emerge or function is affected. Grade B 🟡Case 8 · Rapid weight loss on tirzepatide (muscle, nutrition, monitoring)
What's happening. A patient on tirzepatide is losing weight quickly and is thrilled — but reports poor appetite, low protein intake, fatigue, and little physical activity. The concern isn't the drug working; it's how the weight is coming off.
What should be evaluated. Rate of loss, protein and overall nutritional intake, hydration, muscle and strength, and side-effect burden (nausea, vomiting — dehydration risk). Body composition if available, and micronutrient adequacy. Distinguish lean mass from strength and function.
Treatment options / management. - Protein target + resistance training — the two interventions that best preserve muscle during rapid loss (Grade A 🟢). → Exercise & Muscle - Slow the titration if needed — the fastest possible loss isn't the goal; a sustainable rate with preserved function is. → GLP-1 Side Effects - Nutritional adequacy — ensure enough energy and micronutrients despite reduced appetite.
Trade-offs. Rapid loss feels like success and improves many markers, but muscle loss, nutritional gaps and dehydration are real costs of doing it carelessly. Slowing down trades speed for durability and function.
What would change management. Signs of significant muscle/strength loss, dehydration, persistent vomiting, gallbladder symptoms, or inadequate nutrition would prompt slowing titration, reinforcing protein and resistance training, or reassessing the plan.
Questions patients ask.
Is losing weight fast on tirzepatide a problem?
Fast loss isn't automatically harmful, but doing it with low protein, no resistance training and poor nutrition risks muscle and function. The fix is protein and strength work — and slowing down if needed — not necessarily stopping. Grade A 🟢 → GLP-1 & Muscle LossHow much protein and exercise do I need?
Enough dietary protein and regular resistance training are the evidence-based ways to protect muscle during weight loss; exact targets are individualized with your clinician. Grade A 🟢Case 9 · Regain after stopping semaglutide
What's happening. A patient did well on semaglutide, stopped it (cost, side effects, or "I reached my goal"), and is regaining weight — with returning appetite and "food noise." They feel like they failed. They didn't — this is expected physiology.
What should be evaluated. Why the drug was stopped (cost, access, side effects, misconception that it's a short course), current weight trajectory, appetite, mood, and whether metabolic gains are reversing. Revisit the maintenance plan that should have existed before stopping.
Treatment options. - Reframe obesity as chronic — like hypertension, it often needs ongoing treatment; stopping predictably leads to regain (STEP 1 extension: ~two-thirds of lost weight regained within ~1 year off drug, cardiometabolic gains reversing) (Grade A 🟢). → Weight Regain & Maintenance - Resume or adjust pharmacotherapy, or transition to a maintenance strategy, per shared decision. - Address the actual barrier — if cost/access drove stopping, solve that rather than blaming willpower.
Trade-offs. Restarting means resuming long-term therapy and its costs; not restarting usually means continued regain. Neither is a moral failing — the framing is "which sustainable plan," not "did I fail."
What would change management. The reason for discontinuation (fixable access vs intolerable side effects), pregnancy plans, new contraindications, or a decision to pursue a different long-term strategy (including surgery) would change the path.
Questions patients ask.
I regained weight after stopping — did I fail?
No. Regain after stopping is expected physiology, not weak willpower — trials show most lost weight returns within about a year off the drug. Obesity behaves like a chronic condition that usually needs ongoing treatment. Grade A 🟢 → Weight RegainDo I have to take a GLP-1 forever?
Often, to maintain the benefit — much like blood-pressure medication. Some people transition to other maintenance strategies, but stopping without a plan usually leads to regain. Grade A 🟢Case 10 · Choosing between medication and bariatric surgery
What's happening. A patient with class III obesity (or class II with serious comorbidities) is weighing GLP-1/incretin therapy versus bariatric surgery. Both are legitimate, evidence-based options — the choice is genuinely individual.
What should be evaluated. Degree and duration of obesity, comorbidities (diabetes especially), prior treatment history, eating behaviour, surgical risk, values and preferences, and access/cost. Surgical evaluation is multidisciplinary. → Obesity Workup
Treatment options. - Incretin therapy — substantial average loss (e.g., tirzepatide ~15–21% by dose over 72 weeks, treatment-policy), non-surgical, but ongoing and dependent on continued use. → Tirzepatide - Bariatric surgery — sleeve gastrectomy or Roux-en-Y; ~25–30% total weight loss is common, with strong diabetes-remission rates (especially RYGB) and durable outcomes, at the cost of a procedure, lifelong nutritional follow-up, and surgical risk (Grade A 🟢). → Bariatric Surgery
Trade-offs. Medication avoids surgery but requires indefinite use and access; effect fades if stopped. Surgery is a one-time procedure with larger average, more durable loss and strong diabetes remission, but carries operative risk and lifelong micronutrient monitoring. Increasingly the two are combined or sequenced.
What would change management. Diabetes (favours the durable remission of surgery, esp. RYGB), the magnitude of loss needed, surgical risk, prior medication response, patient preference, and cost/access all move the decision.
Questions patients ask.
Which is better — Ozempic-type drugs or surgery?
Neither is universally "better." Surgery produces larger, more durable average loss and strong diabetes remission but is a procedure with lifelong follow-up; incretins avoid surgery but need ongoing use. The right choice depends on your comorbidities, goals and preferences. Grade A 🟢 → Bariatric SurgeryCan I do both?
Sometimes — medication and surgery are increasingly combined or sequenced, for example to reach a goal or maintain results. It's an individualized decision. Grade B 🟡Case 11 · Incidental fatty liver with normal enzymes
What's happening. An abdominal ultrasound done for another reason reports a "fatty liver." The patient's liver enzymes are normal and they feel well. The reflex is either to panic or to dismiss it — both are wrong. The question isn't whether there's fat; it's whether there's risk.
What should be evaluated. Metabolic risk factors (diabetes/prediabetes, obesity, dyslipidaemia, hypertension), alcohol intake (to classify MASLD vs MetALD), and — the key step — a FIB-4 to stratify advanced-fibrosis risk despite normal enzymes. → Who Should Be Evaluated?
Treatment options. - Risk-stratify first — a low FIB-4 is genuinely reassuring for advanced fibrosis; indeterminate or high prompts elastography. → Diagnostic Approach - Metabolic management — weight loss (≥5% reduces steatosis; ≥7–10% improves MASH) and treating diabetes/lipids/BP addresses both liver and CV risk (Grade A 🟢). → Fatty Liver & Weight Loss
Trade-offs. Ignoring incidental steatosis can miss silent fibrosis; over-reacting to fat alone causes needless anxiety and testing. FIB-4 threads the needle by finding who actually needs more.
What would change management. An indeterminate/high FIB-4, elastography showing significant stiffness, coexisting diabetes, or significant alcohol use (reclassifies as MetALD) would each escalate the workup. → Do I have fatty liver?
Questions patients ask.
My scan says fatty liver but my enzymes are normal — should I worry?
Fat on a scan with normal enzymes is common and usually not an emergency — but normal enzymes don't rule out fibrosis. The right next step is a FIB-4 to stratify risk, not panic and not dismissal. Grade A 🟢 → FIB-4Is fatty liver reversible?
The fat often improves substantially with weight loss and metabolic management — roughly ≥5% loss reduces steatosis. What matters most is preventing or reversing fibrosis, which needs larger, sustained changes. Grade A 🟢Case 12 · Obesity + elevated ALT + high FIB-4
What's happening. A patient with obesity has an elevated ALT and a FIB-4 above 2.67 (high-risk band). Unlike Case 11, this is a signal that warrants prompt, structured evaluation — but a high FIB-4 is still a flag, not a diagnosis.
What should be evaluated. Exclude other causes of elevated enzymes (alcohol, medications, viral hepatitis, other liver disease), confirm the metabolic picture, and proceed to elastography (FibroScan/VCTE or MRE) to better quantify fibrosis. A high FIB-4 generally warrants hepatology referral.
Treatment options. - Fibrosis-directed pathway — elastography, specialist evaluation, and consideration of biopsy in selected uncertain cases. - Metabolic therapy that also helps the liver — substantial sustained weight loss, and where MASH with F2–F3 fibrosis is confirmed, semaglutide 2.4 mg (FDA-approved for MASH, Aug 2025) or resmetirom (first FDA-approved MASH drug, 2024) (Grade A 🟢 for approvals). → MASH Medications
Trade-offs. Acting on FIB-4 alone risks over-calling fibrosis (false positives, especially with age); ignoring it risks missing advancing disease. Elastography and specialist input calibrate the response.
What would change management. Elastography confirming (or excluding) significant/advanced fibrosis, identification of an alternative cause for the ALT, biopsy findings, or confirmed MASH with F2–F3 (opens approved drug therapy) would all change the plan.
Questions patients ask.
My FIB-4 is high — do I have liver scarring?
Not necessarily. A high FIB-4 raises the probability enough to justify the next test (elastography) and often a specialist, but it isn't a diagnosis, and false positives are common, especially with age. Grade A 🟢 → FIB-4Is there a drug for fatty liver now?
Yes, for a specific group: resmetirom and semaglutide 2.4 mg are FDA-approved for noncirrhotic MASH with F2–F3 fibrosis — not for simple fatty liver. Confirming that stage is why elastography and specialist evaluation matter. Grade A 🟢 → MASH MedicationsCase 13 · Metabolic disease + suspected advanced fibrosis
What's happening. A patient with longstanding diabetes and obesity has features suggesting advanced fibrosis — a high FIB-4, elastography with high liver stiffness, perhaps low platelets or imaging hints of early portal changes. The priority shifts from "metabolic optimization" to "protect the liver and stage the disease."
What should be evaluated. Confirm fibrosis stage with elastography (VCTE or MRE) and specialist assessment; consider biopsy where staging is decisive and uncertain. Screen for complications of advanced disease per hepatology (varices, HCC surveillance) and exclude cirrhosis. Full metabolic and CV assessment continues in parallel. → MASLD & Cardiovascular Risk
Treatment options. - Hepatology co-management — staging, surveillance, and complication screening. - Aggressive metabolic therapy — substantial sustained weight loss and diabetes control; note that approved MASH drug therapy (resmetirom, semaglutide 2.4 mg) is for noncirrhotic F2–F3 — advanced/cirrhotic disease is managed differently (Grade A 🟢 on the noncirrhotic limitation). → MASH Medications - CV risk reduction — cardiovascular disease, not the liver, is the leading cause of death in MASLD.
Trade-offs. Confirming stage guides everything — mislabelling cirrhosis as noncirrhotic could mean the wrong drug and missed surveillance. Biopsy adds certainty at the cost of an invasive test, used selectively.
What would change management. Confirmation of cirrhosis (changes drug eligibility and adds surveillance), decompensation, or reclassification to a lower fibrosis stage would substantially alter the plan.
Questions patients ask.
If I have advanced fibrosis, can I still take the new MASH drugs?
The approved MASH drugs are for noncirrhotic F2–F3 fibrosis, not cirrhosis — so confirming your exact stage is essential, and advanced/cirrhotic disease is managed differently with specialist input. Grade A 🟢 → MASH MedicationsIs advanced fibrosis the same as cirrhosis?
No. Fibrosis is scarring on a spectrum; cirrhosis is its most advanced stage. Distinguishing them changes surveillance and treatment, which is why accurate staging matters. Grade A 🟢Case 14 · MASLD + type 2 diabetes
What's happening. A patient has both MASLD and type 2 diabetes — a bidirectional, high-risk pairing. Diabetes drives liver-disease progression, and MASLD worsens metabolic and CV risk. The good news: several therapies help both at once.
What should be evaluated. FIB-4 and, per risk, elastography (a majority of people with type 2 diabetes have MASLD, and diabetes raises the odds of advanced fibrosis). Glycaemic control, CV risk, and lipids. → MASLD & Diabetes
Treatment options. - Dual-purpose therapy — GLP-1/incretin agents improve glycaemia and weight and (semaglutide 2.4 mg) MASH; pioglitazone has MASH evidence; both address the metabolic root (Grade A 🟢 for glycaemic/weight benefit; MASH benefit graded per agent). → Obesity & Diabetes - Substantial sustained weight loss — improves glycaemia and liver histology. - CV risk reduction — central, given the shared risk.
Trade-offs. Choosing agents that help liver, weight and glucose together is efficient, but diabetes management priorities (hypoglycaemia risk, CV indications) still shape drug choice. The plan is genuinely integrated, not liver-only or glucose-only.
What would change management. A high FIB-4 or confirmed advanced fibrosis, established CV disease, or confirmed MASH F2–F3 (opens approved MASH drugs) would each sharpen the approach.
Questions patients ask.
I have diabetes and fatty liver — which do I treat first?
Often the same therapies treat both. GLP-1/incretin agents and substantial weight loss improve glucose, weight and the liver together, so the plan is integrated rather than sequential — with CV risk addressed alongside. Grade A 🟢 → MASLD & DiabetesDoes my diabetes make liver disease worse?
Yes — diabetes drives MASLD progression and raises the risk of advanced fibrosis, which is why fibrosis-risk assessment (FIB-4, then elastography) is recommended in type 2 diabetes. Grade A 🟢Case 15 · Substantial weight loss + improved liver markers (what it does and doesn't prove)
What's happening. A patient loses substantial weight and their ALT normalises, imaging shows less fat, and FIB-4 falls. Everyone's pleased — but what has actually been proven? This case is about interpreting improvement honestly.
What should be evaluated. What each improving marker measures: normalised ALT (less injury), less fat on imaging (reduced steatosis), and a lower FIB-4 (lower estimated fibrosis risk). But fat, injury and fibrosis are three different things — improvement in fat and enzymes does not, by itself, prove fibrosis has regressed. → Fatty Liver & Weight Loss
Interpretation. - Strongly encouraging, genuinely meaningful — weight loss ≥5% reduces steatosis, ≥7–10% improves MASH, and larger sustained loss (~10%+) can improve fibrosis (Grade A 🟢 for the dose-response). → Nutrition for MASLD - But not proof of fibrosis regression — FIB-4 is an estimate, not a measurement; confirming fibrosis change may need elastography over time, and biopsy is rarely used to track it. - Maintenance matters — gains reverse if weight is regained. → Weight Regain
Trade-offs. Over-interpreting improved markers can lead to premature reassurance and stopping effective therapy; under-crediting real improvement is needlessly gloomy. The balanced read: real progress on fat and metabolic risk, with fibrosis change requiring its own confirmation over time.
What would change management. Follow-up elastography showing true fibrosis regression (or persistence), weight regain reversing the gains, or a plateau would each guide next steps.
Questions patients ask.
My liver numbers improved with weight loss — is my liver fixed?
It's real, meaningful progress — less fat and less injury — but improved enzymes and a lower FIB-4 don't by themselves prove scarring has reversed. Fibrosis change is confirmed separately (e.g., elastography over time), and gains can reverse if weight returns. Grade A 🟢 → Fatty Liver & Weight LossHow much weight loss helps the liver?
Roughly: ≥5% reduces liver fat, ≥7–10% improves MASH, and larger sustained loss (~10%+) is generally needed to improve fibrosis. Sustaining it is what protects the gains. Grade A 🟢Questions patients ask
Are these real patients?
No. Every case is a de-identified, composite teaching scenario built to illustrate a common clinical decision. None represents a real individual, and any numbers are illustrative examples. Grade A 🟢
Can I use a case to decide my own treatment?
No — these teach how the reasoning works, not what you specifically should do. Your plan depends on your full picture and is made with a clinician. Two tools can help you prepare: Should I take a GLP-1? and Do I have fatty liver? Grade A 🟢
Why do so many cases end with "it depends"?
Because good obesity and liver medicine is individualized. The same BMI can mean very different things depending on metabolic health, liver fibrosis, muscle, eating behaviour, life stage and goals. That's the whole point of "treat the person, not the scale." Grade A 🟢
Why does fibrosis keep coming up in the liver cases?
Because fibrosis — scarring — is the feature that best predicts liver outcomes, and it can be present even with normal enzymes. Finding fat is easy; finding risk is the job. Grade A 🟢 → FIB-4
Is regain after stopping a medication a personal failure?
No. It's expected physiology — obesity behaves like a chronic condition, and stopping treatment predictably leads to regain. The useful question is which sustainable plan fits, not whether someone "failed." Grade A 🟢 → Weight Regain
How do you decide between medication and surgery?
By weighing the degree and duration of obesity, comorbidities (especially diabetes), prior treatment, surgical risk, preferences and access — not by BMI alone. Both are legitimate, and they're increasingly combined. Grade A 🟢 → Bariatric Surgery
KEEP READING
- The W8Experts Clinical Approach — the Understand · Test · Treat · Sustain method these cases follow.
- Should I take a GLP-1? — the decision tool behind several cases.
- Do I have fatty liver? — the liver-risk tool behind the MASLD cases.
- FIB-4 Explained — the fibrosis-risk filter that recurs throughout.
- Weight Regain & Maintenance — why stopping treatment leads to regain.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: AASLD Practice Guidance on MASLD (2023); STEP and SURMOUNT programmes; SURMOUNT-OSA; diabetes-prevention lifestyle data; guideline-based FIB-4 cutoffs. Cases are composite, de-identified and educational — not real patients, not practice data, and not individualized medical advice.
